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Abstract: MitoNEET is a newly discovered mitochondrial protein
and a target of the TZD class of antidiabetes drugs. MitoNEET
is homodimeric with each protomer binding a [2Fe-2S] center
through a rare 3-Cys and 1-His coordination geometry. Both the
fold and the coordination of the [2Fe-2S] centers suggest that it
could have novel properties compared to other known [2Fe-2S]
proteins. We tested the robustness of mitoNEET to mutation and
the range over which the redox potential (EM) could be tuned.
We found that the protein could tolerate an array of mutations
that modiﬁed the EM of the [2Fe-2S] center over a range of ∼700
mV, which is the largest EM range engineered in an FeS protein
and, importantly, spans the cellular redox range (+200 to -300
mV). These properties make mitoNEET potentially useful for both
physiological studies and industrial applications as a stable, water-
soluble, redox agent.
Iron sulfur (FeS) proteins are integral players in a vast array of
biological activities from redox chemistry in respiration and
photosynthesis to the regulation of transcription and gene expres-
sion.
1 They perform these many diverse functions using only a small
set of different FeS moieties, and their functions are largely derived
from the protein environment around the FeS centers.
1 In particular,
tuning the redox potential (EM) of the FeS center is critical for
controlling the conditions under which the protein responds to its
environment and its interacting partners. As a class, FeS proteins
span a wide redox range
1 under normal cellular conditions,
indicating that FeS centers are fundamentally tunable. This broad
redox range is achieved using several different protein scaffolds.
Progress has recently been made in tuning the EM over a large range
within the same protein scaffold of two non-FeS proteins, a
cupredoxin
2 and a superoxide dismutase.
3 The upper EM limit of
both of these systems is close to +1 V, which indicates that these
proteins could be useful catalysts in key chemical redox processes
such as water oxidation.
1,2 However, neither system could access
the solution potentials in cellular environments (-300 mV to +200
mV).
4 Because different FeS proteins naturally span this range,
1
we rationalized that the EM of a single FeS protein could be
engineered to span both above and below the cellular solution range.
Such a class of proteins could serve as reporters of cellular redox
or be used to perturb the normal redox potential of the cellular
solution. Here, we report our success in tuning the EM of the [2Fe-
2S] center of the outer mitochondrial membrane protein mitoNEET
over a range of 700 mV, which is the largest EM range engineered
in an FeS protein and, importantly, spans the cellular redox range.
MitoNEET is a newly discovered mitochondrial target of the
TZD class of antidiabetes drugs, such as pioglitazone (Actos) and
rosiglitazone (Avandia).
5 Human mitoNEET deﬁnes a unique class
of [2Fe-2S] proteins. The crystal structure shows that mitoNEET
is a homodimer, with each protomer binding a [2Fe-2S] center
through a rare 3-Cys and 1-His coordination geometry (Figure 1).
6
Both the fold and the coordination of the [2Fe-2S] centers suggest
that mitoNEET could have novel properties compared to other
known [2Fe-2S] proteins. For example, the unusual coordination
of the [2Fe-2S] center contributes to the atypical proton-coupled
EM,7 of +25 mV at pH 7.0.
7 We used potentiometric redox
titrations
8 and protein-ﬁlm voltammetry
9 to assess changes in the
EM,7 resulting from mutagenesis of ﬁrst and second shell residues
near the [2Fe-2S] center. Single and double mutations were designed
to test both the robustness of the [2Fe-2S] center and the EM range
that could be achieved. We found that the EM could be tuned over
a wide range (Figure 2, Table S1).
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Figure 1. Protein backbone of the cytoplasmic exposed domain of the
outer-mitochondrial membrane protein mitoNEET (PDB code 2QH7)
showing the redox active [2Fe-2S] centers.
6a MitoNEET is a homodimer,
with one protomer shown in magenta and the other in green. Each protomer
contains a [2Fe-2S] center (shown as spheres) coordinated by 3-Cys and
1-His, with the hallmark single-coordinating His87 indicated. The distance
between the [2Fe-2S] centers is ∼16 Å from center-to-center. His87
coordinates to the outer, more solvent exposed, Fe of the [2Fe-2S] center,
where the electron is predominantly localized upon reduction.
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WT. We had previously shown that the EM of WT mitoNEET is
pH-dependent above neutral pH, indicating that reduction is coupled
to proton uptake.
7,10 Potentiometric redox titrations indicated that
the [2Fe-2S] cluster of mitoNEET undergoes a one-electron
reduction step: [2Fe-2S]2+/[2Fe-2S]+:H (Figure S1). At a pH just
above its pKa in the oxidized state (pKox), uptake of a proton occurs
upon reduction, resulting in a pH-dependence for the EM.
11 This
occurs up to the point where the pH matches the pKa of the proton
in the reduced state (pKred). The most likely candidate for a site of
protonation in the WT mitoNEET is His87 (Figure 3A), which
shows pH-dependent vibrational interactions with the [2Fe-2S]
center.
12 His87 is ligated to the outermost Fe of the [2Fe-2S] center,
where, upon reduction, the additional electron is predominantly
localized.
13 In addition, pulsed EPR studies indicated that His87
is protonated in the reduced state.
13 At the appropriate pH,
protonation of His upon reduction is observed in redox studies on
Rieske type [2Fe-2S] centers that involve His coordination.
14,15
His87 will contribute to the observed proton-coupled reduction
in the pH range above its pKox and below its pKred. In a previous
study, detailed PFV data were ﬁt to two models.
10 Both models
included His87 as an integral player in proton coupling to electron
reduction but differed in the pH range over which protonation of
His87 contributed to the pH dependence. Here, we use direct
UV-vis titration
16 as an independent method to determine the pH
range over which His87 contributes to the proton coupling. This
allows us to distinguish between the two models. We measured
the UV-vis region as a function of pH, as differences in the
absorption peaks are expected to reﬂect the state of protonation of
the titrating ligand.
16 Indeed, changes in the absorbance peak
position of the WT protein in the oxidized state were sensitive to
pH and indicated a titration with an apparent pKa ) 6.8 ( 0.2
(Figure S2A). In addition, peak changes in the reduced state
indicated that the pKred was 12.4 ( 0.2 (Figure S2B). This value is
consistent with values for pKred of ∼12.5 reported for the His ligands
in Rieske centers.
15 The lack of spectral changes in the H87C
mutant conﬁrms the assignment of these changes to the protonation
of His87. Thus, protonation of His87 is predominantly responsible
for the pH-dependence of the EM over the entire range of pH
measured in this study. These new data required a reﬁnement of
the previous model used to describe the pH-dependence data.
10
In the reﬁned model, we explicitly include His87 as a major
contributor to the observed titration across the entire measured range
and implicitly include other groups and pH-dependent effects in a
factor R (eq S5). Fitting of the data to the model (Figure 3B) yields
values of pKox ) 6.7 ( 0.2 and pKred > 11.5 for His87, which is in
agreement with the values determined from UV-vis pH titration,
giving us conﬁdence that the reﬁned model provides an adequate
explanation of the measured data.
We continued our mutant survey by replacing the single
coordinating His ligand (His87) with Cys (Figure 3A). Initial studies
showed that replacement of His87 with Cys (H87C) results in a
signiﬁcantly more stable protein with an EM,7 shifted from +25
mV to -290 mV, decreasing to -360 mV at pH 11.0 (Figure 3B).
The recently determined crystal structure
17 (PDB ID code 3LPQ)
showed that the Sγ of Cys87 in the H87C mutant replaced the Nδ
of His87 in the WT as a ligand of the outer Fe of the [2Fe-2S]
Figure 2. EM values of WT and mutant mitoNEET have been engineered
over a range of ∼700 mV and can be tuned to obtain nearly any value within
the EM range shown. Measurements adjusted to SHE values, with errors
((10 mV) indicated by cross bars. *EM extremes (see Figure 3B). The EM
values of several cellular environments are shown on the left bar. Abbreviations:
Resp. (Respiratory tract ﬂuid, +200 mV),  -Cell (Cytoplasm of beta cells,
producers of insulin in the pancreas, +55 mV), Cyt (Cytoplasm, -205 mV),
ER (Endoplasmic Reticulum, -217 mV), Mito (Mitochondria, -260 mV).
4
Figure 3. (A) Structure near the [2Fe-2S] center (Fe atoms as red spheres,
sulfur as yellow) of mitoNEET showing both the ligating and nearby (<5
Å) titratable residues. (B) Representative pH dependences of the EM for
select mutants. WT, D84G, and D84N exhibit similar dependences (-51
mV/pH) at pH g 7, implying that, in these cases, reduction remains proton-
coupled. H87C shows a more shallow slope (-15 mV/pH) for the pH-
dependence,
10 indicating that His87 is principally responsible for the
observed proton coupling in WT. Replacement of Lys55 with Glu (K55E)
shifts the pKox of His87 from 6.7 ( 0.2 to 9.2 ( 0.2.
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COMMUNICATIONScenter, with no observed long-range structural changes. The shift
to a more negative EM,7 can thus be attributed to the substitution of
the neutral His with an anionic Cys ligand
17 at the 87 site. This
ﬁnding was consistent with previous reports
10 and demonstrates
that His87 is a critical ligand in tuning the EM.
Having established that His87 is a critical ligand in tuning the
EM, we next targeted Lys55, which is located ∼4 Å from His87
(Figure 3A). Based on its close proximity to His87, along with the
observed changes in the side chain conformation of Lys55 in the
H87C mutant,
17 we anticipated that replacing the cationic Lys55
with neutral or negative side chains would increase the pKa of His87
and thereby the EM,7 of the mutant protein.
18 Replacement of Lys55
with the neutral Gln (K55Q) or anionic Glu (K55E) both resulted
in EM,7 values of ∼ +200 mV (Figure 2). The similar EM,7 values
for the K55E and K55Q mutants indicate that their predominant
effect on EM,7 is caused by removal of the cationic Lys. A ﬁt of the
data to the model (eq S5) yielded a pKox of His87 in the K55E that
was shifted by ∼3p Ka units to 9.2 ( 0.2 (Figure 3B). This was
conﬁrmed by optical pH titrations, which gave a value of 9.6 (
0.2 (Figure S2). In the WT, Lys55 makes an interprotomer
interaction with the hydrogen on Nε of His87. Removal of this
H-bond should affect the interprotomer contact, which would have
additional consequences on the stability of the reduced [2Fe-2S]
centers, consistent with the unexpectedly higher EM observed even
at lower pH (Figure 3B). We have shown that replacement of a
charged group next to a coordinating His can dramatically affect
both the pKa of the His and the EM of the [2Fe-2S] center. In the
K55M/H87C double mutant, the EM,7 was -270 mV (Figure 2,
Table S1), close to that of the H87C, supporting the notion that
the predominant effect of Lys55 is through a pKa shift of His87,
which is absent in the double mutant.
Another titratable side chain located near the [2Fe-2S] center is
Asp84 (Figure 3A). Asp84 is within hydrogen bonding distance to
the proximal inorganic sulfur of the [2Fe-2S] center, suggesting
that Asp84 may be in the protonated state. This was conﬁrmed by
replacement with Asn (D84N), which resulted in EM values similar
to the case of the WT over a pH range from 6.0 to 11.0 (Figure
3B). Similar values were obtained upon replacement with Glu
(D84E) and Ser (D84S) (Figure 2, Table S1). The D84S/H87C
double mutant showed that the effects of the two mutations on the
EM,7 were additive (Figure 2, Table S1), which suggests that further
unique EM,7 values could be obtained with double mutants utilizing
sites 84 and 87.
Surprisingly, replacement of Asp84 with Gly (D84G) resulted
in a much more positive EM,7 of +270 mV (Figure 2), increasing
to +305 mV at pH 6.0 (Figure 3B). This is not a result of gross
structural changes, as the optical spectrum of the D84G mutant is
similar to that for the WT (Figure S3). However, the D84G mutation
likely alters the solvent accessibility of the cluster, which has been
shown to strongly affect EM,7 values in other FeS systems, such as
Rieske centers.
19
We have shown that mitoNEET is amenable to manipulation of
residues located near the [2Fe-2S] centers. We were able to tune
EM over a range of ∼700 mV. This system’s resultant range of
EM,7 values is beyond that of any previously reported FeS protein.
Combined with pH modulation, the EM of the [2Fe-2S] center can
be tuned to essentially any value within a range from -360 mV to
+305 mV, making it potentially useful for both physiological
studies and industrial applications as a stable, water-soluble, redox
agent.
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Supporting Information Available: We include a description of
materials and methods. This includes details of pKa values determined
by UV-vis spectral changes as a function of pH and ﬁts of the EM vs
pH. We also include optical redox titration data for all mutants in the
main text as well as others not in the main text (Figure S1). We include
direct UV-vis titrations at different pH for WT and K55E (Figure S2A,
B) and UV-vis absorbance spectra of WT and the D84G (Figure S3).
Cyclic voltammograms for several mutants are shown (Figure S4A-F)
and the values tabulated with the potentiometric data (Table S1). A
comparison of the pH-dependence proﬁles of WT by PFV and
potentiometric titrations is included (Figure S5). This material is
available free of charge via the Internet at http://pubs.acs.org.
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